Genetic Technologies

The company is switching from an insurance-based model to a direct patient self-pay system for its BrevaGenplus breask cancer risk assessment assay.

The company plans to use the proceeds to expand its breast cancer risk test and to develop and commercialize a risk assessment test for colorectal cancer.

The technology involves analyzing susceptibility SNPs in order to predict a patient's likelihood of developing colorectal cancer.

The Australian firm regained compliance with a listing rule requiring a minimum $2.5 million in stockholder equity.

The Australian MDx firm will use the financing to support its medium-term capital needs and the commercialization of its BrevaGenplus test.

The Australian molecular diagnostics firm will use the facility to further commercialize its breast cancer test in the US.

The Australian company will use proceeds to ramp up the commercialization of its breast cancer test.

The transaction is part of Genetic Technologies' restructuring of its operations.

 

 

NEW YORK (GenomeWeb) – Agilent Technologies said on Monday that Genetic Technologies has dismissed its lawsuit against the company alleging patent infringement.

Originally published Oct. 6.

NEW YORK (GenomeWeb) – Genetic Technologies reported that in its first fiscal quarter of 2015 it received close to 950 patient samples for its BREVAGen test for gauging risk of sporadic, non-hereditary breast cancer.

Pages

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.